Prostate cancer topography
More details
Hide details
Department of Urology, Municipal Hospital in Olsztyn, Poland
Department of Pathomorphology, Faculty of Medical Sciences, University of Warmia and Mazury in Olsztyn, Poland
Faculty of Food Sciences, University of Warmia and Mazury in Olsztyn, Poland
Zbigniew Purpurowicz   

Department of Urology, Municipal Hospital in Olsztyn Niepodległości 44, 11-041 Olsztyn, Poland. Tel.: +48 601 894 636.
Submission date: 2014-03-30
Acceptance date: 2015-03-17
Online publication date: 2015-04-19
Publication date: 2020-03-24
Pol. Ann. Med. 2015;22(1):23–25
Prostate cancer is becoming a challenge for modern medicine. It is the second leading cause of cancer-related morbidity and mortality in men, second only to lung cancer. In 2012, 417 000 new cases were registered and 92 000 deaths were reported in Europe. Early detection of prostate cancer allows for complete recovery. Basic diagnostic procedures involve digital rectal examination (DRE), assessment of the serum total prostate specific antigen (PSA) level and transrectal ultrasound (TRUS). Abnormalities detected in these examinations necessitate prostate biopsy.

To evaluate prostate cancer topography based on biopsy.

Material and methods:
Spatial distribution of cancer foci in the prostate was analyzed retrospectively in 246 male patients who had undergone TRUS-guided prostate biopsy. The median age of the study population was 69.7 years. The PSA levels ranged from 0.59 ng/mL to 676.6 ng/mL and the average level was 34.3 ng/mL. During the peribiopsy period, 750 mg of ciprofloxacin was introduced to prevent inflammation, and 100 mg of diclofenac was applied per rectum an hour prior to the procedure to reduce pain.

Results and discussion:
In all 246 patients, tissue core samples were obtained from the prostate, sufficient for histopathological assessment and cancer diagnosis.

TRUS-guided prostate biopsy is an effective method for detecting and locating prostate cancer. Tissue core samples obtained during prostate biopsy serve as sufficient diagnostic material for a histopathologist. In our study population, cancer was located most frequently in the middle part of the prostate gland.

None declared.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403.
Hara R, Jo Y, Fujii T, et al. Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy. Urology. 2008;71(2):191–195.
Djavan B, Milani S, Remzi M. Prostate biopsy: who, how and when. An update. Can J Urol. 2005;12(Suppl 1):44–48. 99–100.
Iczkowski KA, Casella G, Seppala RJ, et al. Needle core length in sextant biopsy influences prostate cancer detection rate. Urology. 2002;59(5):698–703.
Ploussard G, Nicolaiew N, Marchand C, et al. Prospective evaluation of an extended 21-core biopsy scheme as initial prostate cancer diagnostic strategy. Eur Urol. 2014;65(1):154–161.
Moore CM, Robertson NL, Arsanious N, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol. 2013;63(1):125–140.
Siddiqui MM, Rais-Bahrami S, Truong H, et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol. 2013;64(5):713–719.
Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int. 2000;85(6):682–685.
Gołąb A, Soczawa M, Słojewski M, Gliniewicz B, Sikorski A. Topography of the prostate cancer at the initial and next saturation biopsy. Urol Pol. 2008;61(Suppl 1):45–46 [in Polish].
Takahashi H, Epstein JI, Wakui S, Yamamoto T, Furusato B, Zhang M. Differences in prostate cancer grade, stage, and location in radical prostatectomy specimens from United States and Japan. Prostate. 2013;74(3):321–325.
Roethke MC, Kuru TH, Schultze S, et al. Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla. Eur Radiol. 2014;24(2):344–352.